Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ELIZABETH ANN MITTENDORF and KELLY K HUNT.
ELIZABETH ANN MITTENDORF
Connection Strength
11.980
KELLY K HUNT
  1. Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. Ann Surg Oncol. 2017 Nov; 24(12):3502-3509.
    View in: PubMed
    Score: 0.602
  2. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016 Jul 01; 2(7):929-36.
    View in: PubMed
    Score: 0.560
  3. Reply to L. Antolini et al. J Clin Oncol. 2015 Nov 20; 33(33):3978-9.
    View in: PubMed
    Score: 0.527
  4. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol. 2015 Apr 01; 33(10):1119-27.
    View in: PubMed
    Score: 0.502
  5. SLN surgery for clinically node-positive breast cancer patients treated with neoadjuvant therapy. Bull Am Coll Surg. 2014 Jul; 99(7):52-4.
    View in: PubMed
    Score: 0.487
  6. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73.
    View in: PubMed
    Score: 0.483
  7. Following the data: past, present, and future management of the axilla in breast cancer patients. Oncology (Williston Park). 2014 May; 28(5):378, 380, 382.
    View in: PubMed
    Score: 0.481
  8. The controversy regarding margin width in breast cancer: enough is enough. Ann Surg Oncol. 2014 Mar; 21(3):701-3.
    View in: PubMed
    Score: 0.473
  9. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9.
    View in: PubMed
    Score: 0.442
  10. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62.
    View in: PubMed
    Score: 0.390
  11. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010 Jul 08; 29(27):3896-907.
    View in: PubMed
    Score: 0.365
  12. Lymphatic interrupted: do we really understand the risks and consequences? Ann Surg Oncol. 2009 Jul; 16(7):1768-70.
    View in: PubMed
    Score: 0.339
  13. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008 Dec; 15(12):3369-77.
    View in: PubMed
    Score: 0.327
  14. Significance and management of micrometastases in patients with breast cancer. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1451-61.
    View in: PubMed
    Score: 0.305
  15. Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. Ann Surg Oncol. 2020 Dec; 27(Suppl 3):979.
    View in: PubMed
    Score: 0.190
  16. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2).
    View in: PubMed
    Score: 0.190
  17. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. Ann Surg Oncol. 2020 Feb; 27(2):359-366.
    View in: PubMed
    Score: 0.176
  18. SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. Ann Surg Oncol. 2019 Oct; 26(11):3510-3516.
    View in: PubMed
    Score: 0.173
  19. Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence. Surg Clin North Am. 2018 Aug; 98(4):687-702.
    View in: PubMed
    Score: 0.159
  20. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncol. 2018 Feb 01; 4(2):203-209.
    View in: PubMed
    Score: 0.156
  21. Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis. Ann Surg Oncol. 2016 May; 23(5):1508-14.
    View in: PubMed
    Score: 0.136
  22. Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy. J Natl Cancer Inst Monogr. 2015 May; 2015(51):11-4.
    View in: PubMed
    Score: 0.129
  23. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec; 22(13):4270-9.
    View in: PubMed
    Score: 0.129
  24. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014 Oct; 21(11):3440-7.
    View in: PubMed
    Score: 0.121
  25. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
    View in: PubMed
    Score: 0.119
  26. Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol. 2014 Jan; 21(1):60-5.
    View in: PubMed
    Score: 0.115
  27. Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801. Gland Surg. 2013 Aug; 2(3):120-3.
    View in: PubMed
    Score: 0.114
  28. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
    View in: PubMed
    Score: 0.113
  29. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
    View in: PubMed
    Score: 0.112
  30. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013 Jan; 216(1):105-13.
    View in: PubMed
    Score: 0.109
  31. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012 Sep; 256(3):428-36.
    View in: PubMed
    Score: 0.107
  32. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
    View in: PubMed
    Score: 0.107
  33. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012 Oct; 19(10):3177-84.
    View in: PubMed
    Score: 0.106
  34. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83.
    View in: PubMed
    Score: 0.105
  35. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
    View in: PubMed
    Score: 0.104
  36. Surgical considerations in patients receiving neoadjuvant systemic therapy. Future Oncol. 2012 Mar; 8(3):239-50.
    View in: PubMed
    Score: 0.104
  37. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012 Feb 20; 30(6):600-7.
    View in: PubMed
    Score: 0.103
  38. Comparative analysis of clinicopathologic features, treatment, and survival of Asian women with a breast cancer diagnosis residing in the United States. Cancer. 2012 Sep 01; 118(17):4117-25.
    View in: PubMed
    Score: 0.102
  39. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012 Jan; 255(1):109-15.
    View in: PubMed
    Score: 0.102
  40. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
    View in: PubMed
    Score: 0.101
  41. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
    View in: PubMed
    Score: 0.100
  42. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
    View in: PubMed
    Score: 0.100
  43. Response to the letter to the editor: Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: a practice-changing trial. Ann Surg Oncol. 2011 Dec; 18 Suppl 3:S283.
    View in: PubMed
    Score: 0.099
  44. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer. 2010 Dec 01; 10(6):477-82.
    View in: PubMed
    Score: 0.095
  45. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:343-51.
    View in: PubMed
    Score: 0.094
  46. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer. 2010 Feb; 10(1):52-8.
    View in: PubMed
    Score: 0.090
  47. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009 Dec 01; 15(23):7381-8.
    View in: PubMed
    Score: 0.088
  48. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009 Oct; 250(4):558-66.
    View in: PubMed
    Score: 0.088
  49. Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81.
    View in: PubMed
    Score: 0.081
  50. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52.
    View in: PubMed
    Score: 0.077
  51. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283.
    View in: PubMed
    Score: 0.048
  52. Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. Ann Surg Oncol. 2020 Jul; 27(7):2229-2237.
    View in: PubMed
    Score: 0.045
  53. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat. 2019 Jul; 176(2):435-444.
    View in: PubMed
    Score: 0.043
  54. Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. Cancer. 2019 02 01; 125(3):365-373.
    View in: PubMed
    Score: 0.041
  55. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. Support Care Cancer. 2019 Feb; 27(2):495-503.
    View in: PubMed
    Score: 0.040
  56. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol. 2018 Oct; 25(10):2932-2938.
    View in: PubMed
    Score: 0.040
  57. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer. 2018 07 15; 124(14):2923-2930.
    View in: PubMed
    Score: 0.040
  58. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol. 2018 Mar; 210(3):669-676.
    View in: PubMed
    Score: 0.039
  59. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018 08; 18(4):276-281.
    View in: PubMed
    Score: 0.038
  60. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg. 2017 10; 266(4):667-676.
    View in: PubMed
    Score: 0.038
  61. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017 Oct; 24(10):2925-2934.
    View in: PubMed
    Score: 0.038
  62. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018 01; 24(1):28-34.
    View in: PubMed
    Score: 0.037
  63. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. Oncologist. 2017 11; 22(11):1292-1300.
    View in: PubMed
    Score: 0.037
  64. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg. 2017 03; 265(3):574-580.
    View in: PubMed
    Score: 0.037
  65. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659.
    View in: PubMed
    Score: 0.036
  66. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol. 2016 10; 23(10):3190-8.
    View in: PubMed
    Score: 0.035
  67. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol. 2016 10; 23(11):3501-3509.
    View in: PubMed
    Score: 0.035
  68. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg. 2016 Apr; 263(4):802-7.
    View in: PubMed
    Score: 0.034
  69. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8.
    View in: PubMed
    Score: 0.034
  70. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015 Mar; 261(3):547-52.
    View in: PubMed
    Score: 0.032
  71. Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015 Oct 20; 33(30):3386-93.
    View in: PubMed
    Score: 0.032
  72. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015 Feb; 150(2):137-43.
    View in: PubMed
    Score: 0.032
  73. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer. 2015 Feb 17; 112(4):630-5.
    View in: PubMed
    Score: 0.032
  74. Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race. PLoS One. 2014; 9(10):e110281.
    View in: PubMed
    Score: 0.031
  75. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014 Oct; 260(4):608-14; discussion 614-6.
    View in: PubMed
    Score: 0.031
  76. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. PLoS One. 2014; 9(2):e89778.
    View in: PubMed
    Score: 0.030
  77. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61.
    View in: PubMed
    Score: 0.029
  78. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
    View in: PubMed
    Score: 0.029
  79. Comparison of clinicopathologic features and survival in young American women aged 18-39 years in different ethnic groups with breast cancer. Br J Cancer. 2013 Sep 03; 109(5):1302-9.
    View in: PubMed
    Score: 0.029
  80. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012 Oct; 19(10):3152-8.
    View in: PubMed
    Score: 0.027
  81. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. 2012 Dec 15; 118(24):6287-96.
    View in: PubMed
    Score: 0.026
  82. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
    View in: PubMed
    Score: 0.026
  83. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
    View in: PubMed
    Score: 0.026
  84. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012 May; 151(5):710-6.
    View in: PubMed
    Score: 0.026
  85. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011 Oct; 18(11):3164-73.
    View in: PubMed
    Score: 0.025
  86. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):782-7.
    View in: PubMed
    Score: 0.025
  87. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012 Mar 15; 118(6):1507-14.
    View in: PubMed
    Score: 0.025
  88. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24.
    View in: PubMed
    Score: 0.025
  89. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg. 2011 May; 127(5):1763-1772.
    View in: PubMed
    Score: 0.024
  90. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011 Oct; 18(10):2873-8.
    View in: PubMed
    Score: 0.024
  91. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011 Apr; 18(4):932-8.
    View in: PubMed
    Score: 0.024
  92. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010 Oct; 17 Suppl 3:280-5.
    View in: PubMed
    Score: 0.023
  93. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47.
    View in: PubMed
    Score: 0.023
  94. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
    View in: PubMed
    Score: 0.023
  95. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9.
    View in: PubMed
    Score: 0.023
  96. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8.
    View in: PubMed
    Score: 0.023
  97. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
    View in: PubMed
    Score: 0.023
  98. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):1821-8.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.